Please login to the form below

Not currently logged in
Email:
Password:

Meda appoints Maria Carell regional director for the US

She joins the Swedish speciality pharma company with management experience from Novartis, Actavis and Q-Med

Swedish speciality pharma company Meda has appointed Maria Carell to a senior management position at its US operations.

She has sat on the firm's board for almost a year and will now take up the role of regional director for the US as Meda waits for a decision from the Food and Drug Administration (FDA) on its rhinitis treatment Dymista.

The US regulator is due to decide in early May on Dymista (azelastine hydrochloride and fluticasone propionate), a nasal spray formulation for patients 12 years and older with seasonal allergic rhinitis.

"Maria Carell will be an important addition to the team that prepares the launch of Dymista in the US", said Anders Lönner, Meda's CEO.

She joins Meda with extensive experience in the health care sector, including management positions at Novartis, generics company Actavis and medical device firm Q-Med.

Following Carell's appointment to the US regional role she has declined re-election to Meda's board.

18th April 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics